17 Greenberg Traurig Attorneys Named “Life Science Stars” in LMG Life Sciences 2017 Guide
(PRWEB) September 19, 2017 -- The LMG Life Sciences 2017 Guide’s “Life Science Stars” includes 17 attorneys from global law firm Greenberg Traurig, LLP. David J. Dykeman, patent attorney, co-chair of the firm’s global Life Sciences & Medical Technology Group and the Intellectual Property (IP) Group in Boston, was also shortlisted for “Patent Strategy & Management Attorney of the Year – Massachusetts.”
In addition to individual attorney rankings, Greenberg Traurig was listed as a “Recommended Firm” in the following practice areas:
• M&A
• Hatch-Waxman (Generic)
• Patent Prosecution
• Patent Strategy & Management
The LMG Life Sciences Guide serves as a resource for in-house counsel identifying leading lawyers and firms in multiple practice areas.
The Greenberg Traurig attorneys named “Life Science Stars” are:
Jonathan D. Ball, Ph.D. is a shareholder in the firm’s New York office with over 15 years of experience representing clients in intellectual property matters, with an emphasis on patent litigation and contentious Patent Office proceedings. He also has broad experience in patent portfolio management, prosecution, and licensing, and helps companies develop and implement worldwide IP strategies. Dr. Ball also handles appeals to the Court of Appeals for the Federal Circuit.
Scott J. Bornstein is co-chair of the firm's Global Intellectual Property & Technology Practice; chair of the firm's New York Intellectual Property & Technology Practice; co-chair of the firm's Global Patent Litigation Group; serves on the firm’s Executive Committee; and is a shareholder in the firm’s New York office. Bornstein has wide-ranging patent trial experience and has served as lead counsel in more than 100 patent litigations for a wide variety of national and international clients.
Robert P. Charrow, a shareholder in the firm’s Washington, D.C. office, focuses his practice on research, biotechnology, and health care issues. He represents health care providers, scientists, pharmaceutical companies, universities, research institutes, and other entities with respect to legislative, regulatory, and litigation matters arising under various federal laws and regulations.
Lori G. Cohen is chair of the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice; chair of the Trial Practice; co-chair of the Atlanta Litigation Practice; and is a shareholder in the firm’s Atlanta office. Her national litigation practice focuses on product liability litigation and, specifically, medical device and pharmaceutical litigation. Cohen has obtained 57 defense verdicts at trial.
Karen C. Corallo is a shareholder in the firm’s Washington, D.C. office, and represents pharmaceutical and medical device industry clients in litigation and counsels businesses on administrative, regulatory, and enforcement matters. As the former Director of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Division of Drug Imports, Exports, Recalls, and Shortages, Corallo authored and executed the Agency’s global drug imports strategy, managed operations and supervised staff, and spearheaded important drug policy initiatives for the Agency.
David J. Dykeman, co-chair of the firm’s Global Life Sciences & Medical Technology Group, co-chair of firm’s Boston IP Group, and a shareholder in the firm’s Boston office, is a registered patent attorney with more than 20 years of experience in patent and intellectual property law. Dykeman’s practice focuses on securing worldwide intellectual property protection and related business strategy for high-tech clients, with particular experience in life sciences, medical devices, biotechnology, health care, and information technology.
Wayne H. Elowe is chair of the Atlanta Corporate and Securities Practice and concentrates his practice on international business and complex commercial transactions, with an emphasis on mergers and acquisitions, joint ventures, strategic alliances, licensing, and technology transactions. He represents publicly traded and privately held multinational corporations, private equity funds and other investors in various industries, including information technology, media, health care, pharmaceutical, manufacturing, telecommunications, outsourcing, chemical and food.
Robert L. Grossman, co-chair of the firm’s Israel Practice and a shareholder in the firm’s Miami office, focuses on securities, M&A, and corporate law with a wide-range of experience in taking companies public as well as acquiring and selling companies. Grossman has represented public and private companies, including companies in the medical device, pharmaceutical, biotechnology, health care, energy and natural resources, technology and software, and communications industries.
Melissa Hunter-Ensor, Ph.D., a shareholder and registered patent attorney in the firm’s Boston office, focuses her practice on the intellectual property and commercial needs of clients in the life science industry. She has experience representing clients throughout the business cycle with patent portfolio management and strategic alliances, litigation and pre-litigation strategy, as well as in assessing the IP risks of target investments and conducting IP patent and licensing due diligence.
Allan Kassenoff is a litigator in the firm’s New York office with 18 years of experience in patent matters covering a wide range of technologies and industry sectors, including financial services, aerospace, automotive, avionics, biotechnology, chemical, consumer products, electronics, and pharmaceutical. In addition to having taken hundreds of depositions and arguing motions and conducting Markman hearings in federal courts throughout the country, he has tried four patent cases to verdict.
David C. Peck, co-chair of the Life Sciences & Medical Technology Group and a shareholder in the firm’s Fort Lauderdale office, works with emerging growth companies, established entities, and private equity firms in executing their strategic plans. He assists companies beginning with corporate formation, obtaining and structuring both equity and debt financing, mergers and acquisitions, as well as the integration of acquired operations, undertaking initial public offerings, and continuing through to liquidity and exit strategies.
Richard C. Pettus, shareholder in the firm’s New York office, has 20 years of experience in the litigation and trial of patent matters in the pharmaceutical and medical device fields, with a particular focus on Paragraph IV Hatch-Waxman litigation. He has represented clients in over 60 patent litigations, including more than 10 trials to verdict, and dozens of other matters that were successfully resolved via pre-trial dismissals, summary judgments and pro-competitive settlements.
Ginger Pigott, vice-chair of the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and a shareholder in the firm’s Los Angeles office, focuses her practice on products liability litigation. A particular focus of her practice lies in the defense of complex medical device and pharmaceutical products liability litigation through trial, as well as counseling on pre-litigation issues including risk assessment, exposure reduction and mitigation and claims handling.
Justin J. Prochnow, a shareholder in the firm’s Denver office, focuses his practice on assisting companies with regulatory, business, and legal needs in the beverage, food, dietary supplement, cosmetic, medical device, and OTC industries. Prochnow works closely with companies to ensure regulatory compliance with statutes and regulations enforced by the Food and Drug Administration, the Federal Trade Commission, and other regulatory agencies.
Barry J. Schindler, co-chair of the firm’s Global Patent Prosecution Group and shareholder in the firm’s New Jersey office, has more than 25 years of experience in all aspects of pharmaceutical and chemical patent prosecution, representing major pharmaceutical and chemical companies regarding patents relating to small molecules and synthetic compounds. Schindler also focuses his practice on managing the patent portfolio and IP transaction for dozens of innovative Israeli pharmaceutical and life science startups and numerous Israeli pharmaceutical and life science incubators. Schindler is also the leading IP transaction attorney for numerous major VC’s in biotech and healthcare. And, Schindler has broad experience in the area of IPR as well as periodically presenting at the USPTO and presenting numerous seminars regarding the strategic use of the new AIA post-grant proceedings.
Nancy E. Taylor, co-chair of the Health & FDA Business Practice and shareholder in the firm’s Washington, D.C. office, has broad experience in areas relating to the Affordable Care Act provisions, CMS reimbursement, and policy issues relating to providers and plans, and she has done a significant amount of FDA regulatory work. Before joining Greenberg Traurig, Taylor served 10 years as Health Policy Director for the Senate Committee on Labor and Human Resources.
Fang Xie, Ph.D., of counsel in the firm’s Boston office, co‐leads the firm’s Biotechnology and Pharmaceutical Group. Dr. Xie focuses her practice on establishing, defending, licensing, sharing and monetizing intellectual property rights for life sciences companies. She has broad experience in worldwide patent portfolio development, intellectual property due diligence, licensing and technology transfer, patentability and product clearance studies, validity/invalidity analyses, patent infringement evaluations, as well as intellectual property litigation and pre-litigation counseling.
About LMG Life Sciences
According to its website, LMG Life Sciences’ research involved over 1,000 online surveys and interviews with nearly 600 attorneys in the United States, as well as a review of public information and feedback from clients within the industry. This qualitative process of peer opinion, market feedback, and independent research led to their list of highest profile, most sought-after, and best-attorneys working in life sciences.
About Greenberg Traurig’s Life Sciences & Medical Technology Group
Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.
About Greenberg Traurig, LLP
Greenberg Traurig, LLP (GTLaw) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East and is celebrating its 50th anniversary. GTLaw has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and among the Top 20 on the 2016 Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.
Lourdes Brezo Martinez, Greenberg Traurig, +1 (212) 801-2131, [email protected]
Share this article